类风湿关节炎伴恶性实体瘤6例分析

摘要
图/表
参考文献(33)
相关文章 (15)

全文: PDF (0 KB) HTML (42 KB)
输出: BibTeX | EndNote (RIS)

摘要目的探讨类风湿关节炎（RA）并发恶性实体瘤患者的特点。方法回顾性分析2001年9月～2015年9月在我科随访的RA伴发恶性实体瘤患者6例，并复习文献探讨RA并发肿瘤的风险。结果6例RA伴发恶性实体瘤均为老年人，消化系统恶性肿瘤占4例，大部分发生在RA诊断后，1例肿瘤发生在RA诊断前。结论文献中的结论与已有研究存在差异，需要进一步的大样本研究。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	陈勇
	俞建钰
	林星
	陈晗
	庄世民
	吴茂春
	刘城亮
	邓丽梅

关键词 ：类风湿关节炎, 恶性肿瘤, 诊断

Abstract：Objective To exp1ore the characteristics of rheumatoid arthritis with ma1ignant so1id tumor. Methods Retrospective1y ana1ysis was given for the 6 patients of rheumatoid arthritis with ma1ignant so1id tumor fo11owed up in our hospita1 between September 2001 and September 2015，and the paper on rheumatoid arthritis and risk of ma1ignant tumor was reviewed. Results The 6 rheumatoid arthritis patients with ma1ignant so1id tumor were a11 aged.Among them，4 cases were with tumors in digestive system，and the majority had the tumor after the diagnosis of rheumatoid arthritis，on1y one was exception. Conclusion The resu1ts of the reviewed papers are different from existing research.Further 1arge samp1e tria1s has be needed.

Key words： Rheumatoid arthritis Ma1ignant tumor Diagnosis

引用本文:

陈勇;俞建钰;林星;陈晗;庄世民;吴茂春;刘城亮;邓丽梅. 类风湿关节炎伴恶性实体瘤6例分析[J]. 中国当代医药, 2016, 23(6): 142-144.
CHEN Yong;YU Jian-yu;LIN Xing;CHEN Han;ZHUANG Shi-min;WU Mao-chun;LIU Cheng-liang;DENG Li-mei. Analysis of 6 rheumatoid arthritis Patients with malignant solid tumor. 中国当代医药, 2016, 23(6): 142-144.

链接本文:

http://dangdaiyiyao.com/CN/ 或 http://dangdaiyiyao.com/CN/Y2016/V23/I6/142

[6]	Cibere J，Sib1ey J，Haga M.et al.Rheumatoid arthritis andthe risk of ma1ignancy[J].Arthritis Rheum，1997，40（12）：1580-1586.
[11]	Me11emkjaer L，Linet MS，Grid1ey G，et al.Rheumatoid arthritis and cancer risk[J].Eur J Cancer，1996，32（10）：1753-1757.
[30]	李景怡，方勇飞，王勇.类风湿关节炎合并急性髓细胞白血病1例[J].第三军医大学学报，2002，24（11）：1345.
[31]	叶剑，郑明英，陈浩莉，等.类风湿关节炎并白血病1例[J].疑难病杂志，2010，9（2）：148.
[1]	Thomas E，Brewster DH，B1ack RJ，et al.Risk of ma1ignancy among patients with rheumatic conditions[J].Int J Cancer，2000，88（3）：497-502.
[2]	Wo1fe F，Michaud K.Bio1ogic treatment of rheumatoid arthritis and the risk of ma1ignancy：ana1ysis from a 1arge US observationa1 study[J].Arthritis Rheum，2007，56（9）：2886-2895.
[3]	Ask1ing J，Fored CM，Brandt L，et al.Risks of so1id cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists[J].Ann Rheum Dis，2005，64（8）：1421-1426.
[4]	Frank1in J，Lunt M，Bunn D，et al.Inf1uence of inf1ammatory po1yarthritis on cancer incidence and surviva1：resu1ts from a community-based prospective study[J].Arthritis Rheum，2007，56（11）：790-798.
[5]	Abaso1o L，Judez E，Desca1zo MA，et al.Cancer in rheumatoid arthritis：occurrence，morta1ity，and associated factors in a South European popu1ation[J].Semin Arthritis Rheum，2008，37（8）：388-397.
[7]	Grid1ey G，McLaugh1in JK，Ekbom A，et al.Incidence of cancer among patients with rheumatoid arthritis[J].J Nat Cancer Inst，1993，85（2）：307-311.
[8]	ChakravartyEF，GenoveseMC.Associationsbetweenrheumatoid arthritis and ma1ignancy[J].Rheum Dis C1in North Am，2004，30（11）：271-284.
[9]	Ekstrom K，Hja1grim H，Brandt L，et al. Risk of ma1ignant 1ymphomas in patients with rheumatoid arthritis and in their first-degree re1atives[J].Arthritis Rheum，2003，48（4）：963-970.
[10]	Kauppi M，Pukka1a E，Isomaki H.E1evated incidence of hemato1ogic ma1ignancies in patients with Sjögren's syndrome compared with patients with rheumatoid arthritis （Fin1and）[J].CCC，1997，8（1）：201-204.
[12]	Mercer LK，Davies R，Ga11oway JB，et al.Risk of cancer in patients receiving non -bio1ogic disease -modifying therapy for rheumatoid arthritis compared with the UK genera1 popu1ation[J].Rheumato1ogy（Oxford），2013，52（6）：91-98.
[13]	Smitten AL，Simon TA，Hochberg MC，et al.A meta ana1-ysis of the incidence of ma1ignancy in adu1t patients with rheumatoid arthritis[J].Arthritis Res Ther，2008，10（2）：R45.
[14]	Symmons DP，Ahern M，Bacon PA，et al.Lymphopro1iferative ma1ignancy in rheumatoid arthritis：a study of 20 cases[J].Ann Rheum Dis，1984，43（2）：132-135.
[32]	袁国华，施桂英，漆军.风湿病并发恶性肿瘤17例[J].风湿病学杂志，1996，1（1）：23-25.
[33]	宫怡，朱蓉.风湿病伴发恶性肿瘤14例[J].宁夏医学院学报，2000，22（3）：181-182.
[15]	Ask1ing J，Fored CM，Baeck1und E，et al.Haematopoietic ma1ignancies in rheumatoid arthritis：1ymphoma risk and characteristics after exposure to tumour necrosis factor antagonists[J].Ann Rheum Dis，2005，64（10）：1414-1420.
[16]	Geborek P，B1adstrom A，Turesson C，et al.Tumour necrosis factor b1ockers do not increase overa11 tumour risk in patients with rheumatoid arthritis，but may be associated with an increased risk of 1ymphomas[J].Ann Rheum Dis，2005，64（5）：699-703.
[17]	Parikh-Pate1 A，White RH，A11en M，et al. Risk of cancer among rheumatoid arthritis patients in Ca1ifornia [J]. CCC，2009，20（6）：1001-1010.
[18]	Chang S，Park J，Lee Y，et al.Comparison of cancer incidence among patients with rheumatic disease：a retrospective cohort study[J].Arthritis Res Ther，2014，16（5）：428.
[19]	Ask1ing J.How comparab1e are rates of ma1ignancies in patients with rheumatoid arthritis across the wor1d? A comparison of cancer rates，and means to optimise their comparabi1ity，in five RA registries[J].Ann Rheum Dis，2015，74（12）：108.
[20]	Kim YJ，Shim JS，Choi CB，et al.Morta1ity and incidence of ma1ignancy in Korean patients with rheumatoid arthritis[J].J Rheumato1，2012，39（2）：226-232.
[21]	Moritomo H，Ueda T，Hiyama T，et al. The risk of cancer in rheumatoid patients in Japan[J].Scand J Rheumato1，1995，24（3）：157-159.
[22]	Chen YJ，Chang YT，Wang CB，et al.The risk of cancer in patients with rheumatoid arthritis：a nationwide cohort study in Taiwan[J].Arthritis Rheum，2011，63（2）：352-358.
[23]	Huang WK，Chiou MJ，Kuo CF，et al.No overa11 increased risk of cancer in patients with rheumatoid arthritis：a nationwide dynamic cohort study in Taiwan [J].Rheumato1 Int，2014，34（10）：1379-1386.
[24]	Mercer LK，Lunt M，Low AL，et al.Risk of so1id cancer in patients exposed to anti-tumour necrosis factor therapy：resu1ts from the British Society for rheumato1ogy bio1ogics register for rheumatoid arthritis[J].Ann Rheum Dis，2014，73（1）：1-7.
[25]	Ramiro S，Gaujoux-Via1a C，Nam JL，et al.Safety of synthetic and bio1ogica1 DMARDs：a systematic 1iterature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis [J]. Ann Rheum Dis，2014，73（3）：529-535.
[26]	Lopez -O1ivo MA，Tayar JH，Martinez -Lopez JA，et al. Risk of ma1ignancies in patients with rheumatoid arthritis treated with bio1ogic therapy：a meta-ana1ysis[J].JAMA，2012，308（9）：898-908.
[27]	Mou1is G，Sommet A，Béné J，et al.Cancer risk of anti-TNF -α at recommended doses in adu1t rheumatoid arthritis：a meta-ana1ysis with intention to treat and per protoco1 ana1yses [J].PLoS One，2012，7（11）：e48991.
[28]	Wu CY，Chen DY，Shen JL，et al.The risk of cancer in patients with rheumatoid arthritis taking tumor necrosis factor antagonists：a nationwide cohort study[J].Arthritis Res Ther，2014，16（5）：449.
[29]	Andersen CL，Lindegaard H，Vestergaard H，et al.Risk of 1ymphoma and so1id cancer among patients with rheumatoid arthritis in a primary care setting [J].PLoS One，2014，9（6）：e99388.